Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study (Q102139902)
Jump to navigation
Jump to search
scientific article published on 17 November 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study |
scientific article published on 17 November 2020 |
Statements
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study (English)
Daniela Pugliese
Francesca Rogai
Angela Variola
Lucrezia Laterza
Antonino Carlo Privitera
Mariangela Allocca
Fabrizio Bossa
Maria Cappello
Marco Daperno
Greta Lorenzon
Silvia Mazzuoli
Mariabeatrice Principi
Renato Sablich
Luisa Moser
Antonio Ferronato
Sara Traini
Gherardo Tapete
Giorgia Bodini
Maria Di Girolamo
Laurino Grossi
Giammarco Mocci
Chiara Ricci
Rocco Spagnuolo
Claudio Camillo Cortelezzi
Filippo Mocciaro
Fernando Rizzello
on behalf on the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
17 November 2020
2050640620974308